血液系统恶性肿瘤随机对照试验的入选标准与不良事件之间的关系
本研究检索2010年1月至2015年1月发表于高影响力期刊的血液系统恶性肿瘤随机对照试验,共97项,其中白血病33%、淋巴瘤28%、多发性骨髓瘤34%、骨髓增生异常综合征或骨髓纤维化5%。分析发现心脏、肝脏和肾脏的入选标准与预期毒性不相关,肝脏和肾脏入选标准与观察到的的不良事件也不相关(P=0.69和P=0.77),但心脏入选标准与观察到的的不良事件显著相关(P=0.02)。
要点
- 在≥10%、≥5%和<5%阈值下,预期毒性与心脏、肝脏、肾脏入选标准均不相关。
- 肝脏和肾脏入选标准与观察到的的不良事件不相关(P=0.69和P=0.77)。
- 心脏入选标准与观察到的的不良事件显著相关(P=0.02)。
核心结论
- 所分析的排除器官功能障碍患者的随机对照试验,其入选标准并不反映基于处方药标签/既往经验预期的毒性或试验中报告的不良事件。
研究设计与样本
- 检索MEDLINE从2010年1月至2015年1月发表于高影响力期刊的血液系统恶性肿瘤随机对照试验,共纳入97项试验。
主要发现
- 97项试验中,白血病33%、淋巴瘤28%、多发性骨髓瘤34%、骨髓增生异常综合征或骨髓纤维化5%。
- 在≥10%、≥5%和<5%阈值下,预期毒性与心脏、肝脏或肾脏入选标准不相关(逻辑回归)。
- 采用改良McNemar检验,在每个阈值下肝脏、肾脏和心脏预期毒性与入选标准均显著不一致。
- 肝脏和肾脏入选标准与观察到的的不良事件不相关,P=0.69和P=0.77。
- 心脏入选标准与观察到的的不良事件显著相关,P=0.02。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To minimize adverse events (AEs) unrelated to drugs and maximize the likelihood of drug approvals, eligibility criteria for randomized controlled trials (RCTs) may be overly restrictive. The purpose of this study was to determine if RCTs in hematologic malignancies exclude patients irrespective of known toxicities or observed AEs. MEDLINE was searched from 1/2010 to 1/2015 for RCTs published in high-impact journals. Of 97 trials, 33% were conducted in leukemia, 28% in lymphoma, 34% in multiple myeloma and 5% in myelodysplastic syndromes or myelofibrosis. Expected toxicities at thresholds of ⩾10%, ⩾5% and <5% were not correlated with cardiac, hepatic or renal eligibility criteria (logistic regression). To explore this lack of correlation we tested the concordance of expected toxicities and eligibility criteria using a modified version of McNemar's test: at each threshold, hepatic, renal and cardiac expected toxicities were significantly discordant with eligibility criteria. Hepatic and renal eligibility criteria were also not correlated with observed AEs, P=0.69 and P=0.77, respectively, but a significant correlation was detected between cardiac eligibility criteria and observed AEs, P=0.02. Thus, the analyzed RCTs excluding patients with organ dysfunction do not reflect expected toxicities, based on prescription drug labels/prior experience, or reported AEs on the trials.
引用
- Statler A, Radivoyevitch T, Siebenaller C, et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia. 2016. PMID: 27924815. doi:10.1038/leu.2016.374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。